Eli Lilly's bid for approval for an experimental weight-loss pill got a boost on Wednesday with new clinical trial data, and ...

Eli Lilly's orforglipron beat NVO's Rybelsus in a 52-week diabetes study, showing stronger A1C and weight loss benefits.

Eli Lilly and Company (NYSE:LLY) is among the high growth mega cap stocks you can buy and hold for the next 3 years. During the first quarter, eCIO Inc.

Makers of GLP-1 drugs, including Novo Nordisk and Eli Lilly, are close to releasing pills taken daily to help shed pounds as an alternative to weekly injections.

Ousted CDC director Susan Monarez says Kennedy planned to change pediatric vaccine schedule; Eli Lilly’s obesity pill beats Novo’s Rybelsus in latest study; Novo views semaglutide trial in Alzheimer’s ...